Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Nursing Care Insurance Boosts Market for Welfare Appliances
February 19, 2001
- GSK Appeals to Tokyo High Court in Aciclovir Patent Dispute
February 19, 2001
- Merger of Medical, Nursing Care Insurance Programs Proposed: JMA Symposium
February 19, 2001
- About Half of Hospitals Reuse Single Use Devices
February 19, 2001
- BUSINESS NEWS IN BRIEF -1-
February 19, 2001
- Nat'l Univ Hospitals Directors Council to Propose One Record per Patient
February 19, 2001
- Hitachi Medical Transfers Nursing Care Business to Group Company
February 19, 2001
- BUSINESS NEWS IN BRIEF -2-
February 19, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 19, 2001
- Boston Scientific Ties Up with Islaeri, Canadian Firms in Cardiac Electrophysiology
February 19, 2001
- PMSB to Draft Criteria for Disclosure of Information
February 19, 2001
- Takara Shuzo Ties Up with GenCom for Genomic Analysis of ES Cells
February 19, 2001
- Mitsubishi Chemical Licenses SPR Technology from Quantech
February 19, 2001
- Delisting Should Be Considered for Certain Drugs: Finance Ministry Officer
February 19, 2001
- Nihon Nosan Kogyo Forms Alliance with PPL Therapeutics of UK for Genomic Technology
February 19, 2001
- Japan, EU Mutual GMP Recognition Coming Soon
February 19, 2001
- Society to Request 3-month Prescription Periods for Anti-HIV Drugs
February 19, 2001
- Price of Seroquel Is 4 Times Higher Than Lullan
February 19, 2001
- RA Patient Group Holds Survey on Clinical Trials
February 19, 2001
- Long, Short-term Goals Must Be Set for Reform: JMA President
February 19, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…